Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
494 studies found for:    "Fallopian tube cancer"
Show Display Options
Rank Status Study
21 Terminated
Has Results
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: regorafenib
22 Suspended A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention: Drug: D4064A
23 Terminated
Has Results
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Serous Cancer;   Fallopian Tube Cancer
Intervention: Drug: bevacizumab
24 Unknown  Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis
25 Recruiting Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Intervention: Biological: Autologous Monocytes + ACTIMMUNE + SYLATRON
26 Completed Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: intravenous docetaxel with intraperitoneal oxaliplatin;   Drug: intravenous oxaliplatin with intraperitoneal docetaxel
27 Completed
Has Results
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Placebo;   Drug: Gemcitabine;   Drug: Pertuzumab
28 Recruiting Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Paclitaxel,;   Drug: Bevacizumab;   Drug: Cisplatin;   Drug: Olaparib
29 Completed
Has Results
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary PERITONEUM;   Fallopian Tube Cancer
Intervention: Drug: Paclitaxel,Cisplatin, Bevacizumab
30 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Floxuridine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
31 Active, not recruiting Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
32 Terminated Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: gemcitabine hydrochloride;   Drug: topotecan hydrochloride
33 Terminated Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Bowel Obstruction
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
34 Completed Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer
Interventions: Drug: TCG;   Drug: TC
35 Terminated
Has Results
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: SJG-136;   Other: laboratory biomarker analysis
36 Recruiting Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride
37 Not yet recruiting A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Neoadjuvant Treatment;   Debulking Surgical Procedures
Interventions: Drug: Olaparib;   Drug: Platinum-based Chemotherapy
38 Suspended Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
39 Completed
Has Results
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Sorafenib Tosylate
40 Recruiting PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Ovarian Cancer
Interventions: Drug: IMGN853;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Topotecan

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.